Skip NavigationSkip to Content

Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex

  1. Author:
    Brooks, A. D.
    Jacobsen, K. M.
    Li, W. Q.
    Shanker, A.
    Sayers, T. J.
  2. Author Address

    [Brooks, Alan D.; Jacobsen, Kristen M.; Shanker, Anil; Sayers, Thomas J.] NCI, Expt Immunol Lab, Frederick, MD 21702 USA. [Brooks, Alan D.; Shanker, Anil; Sayers, Thomas J.] Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA. [Li, Wenqing] NCI, Canc & Inflammat Program, Mol Immunoregulat Lab, Frederick, MD 21702 USA.;Sayers, TJ, NCI, Expt Immunol Lab, Frederick, MD 21702 USA.;sayerst@mail.nih.gov
    1. Year: 2010
    2. Date: May
    3. Epub Date: 5/6/2010
  1. Journal: Molecular Cancer Research
    1. 8
    2. 5
    3. Pages: 729-738
  2. Type of Article: Article
  3. ISSN: 1541-7786
  1. Abstract:

    Bortezomib (VELCADE) could sensitize certain human renal cell carcinoma (RCC) lines to the apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Analysis of seven human RCC showed a clear increase in the sensitivity of four of the RCC to TRAIL cytotoxicity following bortezomib (5-20 nmol/L) treatment, whereas the remaining three remained resistant. Tumor cell death following sensitization had all the features of apoptosis. The enhanced antitumor activity of the bortezomib and TRAIL combination was confirmed in long-term (6 days) cancer cell outgrowth assays. The extent of proteasome inhibition by bortezomib in the various RCC was equivalent. Following bortezomib treatment, neither changes in the intracellular protein levels of various Bcl-2 and IAP family members, nor minor changes in expression of TRAIL receptors (DR4, DR5), correlated well with the sensitization or resistance of RCC to TRAIL-mediated apoptosis. However, enhanced procaspase-8 activation following bortezomib pretreatment and subsequent TRAIL exposure was only observed in the sensitized RCC in both cell extracts and death-inducing signaling complex immunoprecipitates. These data suggest that the molecular basis for bortezomib sensitization of RCC to TRAIL primarily involves early amplification of caspase-8 activity. In the absence of this increased caspase-8 activation, other bortezomib-induced changes are not sufficient to sensitize RCC to TRAIL-mediated apoptosis. Mol Cancer Res; 8(5); 729-38. (C)2010 AACR.

    See More

External Sources

  1. DOI: 10.1158/1541-7786.mcr-10-0022
  2. PMID: 20442297
  3. PMCID: PMC2873082
  4. WOS: 000278487100009
  5. NIHMSID: Nihms194191

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel